Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 31 - 40 of 333

<< Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next >>

Last updated: 20th February 2008

Patent No.: WO 084131
Furin inhibitors and alpha-defensins for the treatment or prevention of papillomavirus infection.
Applicant: Day PM, Richards R, Buck C, Schiller JT, Lowy DR (2006)
The present invention includes a method for inhibiting papillomavirus infection in a human comprising administering to a human at risk thereof a furin inhibitor or alpha-defensin, a method of inhibiting papillomavirus infection in a human comprising transfecting a cell in vivo with an nucleic acid comprising a nucleotide sequence encoding a furin inhibitor or alpha-defensin, a method for detg. whether a compd. modulates furin inhibitor or alpha-defensin activity in a cell, and a method for inhibiting papillomavirus infection in a human comprising administering to the human an identified compd. to augment furin inhibitor or alpha-defensin activity.

Patent No.: WO 058395
Methods for quantitating copy no. of beta-defensin genes associated with lung disorders using real-time PCR.
Applicant: Cuppens H, Nuytten H, Cassiman J-J (2006)
The invention relates to methods for quantitating copy no. of beta-defensin genes 1-6 assocd. with lung disorders using real-time PCR. Lung disorders may include chronic obstructive pulmonary disorder, cystic fibrosis and emphysema. Methods for detg. genetic susceptibility for lung disorders or diagnosis of said disorders are provided.

Patent No.: WO 053565
Protein and cDNA sequences and heterologous expression of antimicrobial peptides from spruce, oyster and scorpion, and uses thereof.
Applicant: Segura DR, Mygind PH, Hansen MT, Soerensen MV, Sandvang D (2006)
The present invention relates to defensin family polypeptides having antimicrobial activity and polynucleotides encoding the polypeptides which may be discovered using Hidden Markov Model search. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. Specifically, the invention provides sequences for precursors, mature peptides and encoding nucleotides for "Piceasin" from the spruce Picea glauca, "Virgisin-1" and "Virgisin-2" from the oyster Crassostrea virginica, "Oystrisin" from the oyster Crassostrea Oystrisin, and "Gibbosin" from the scorpion Mesobuthus gibbosus. Antimicrobial activity for the above peptides was demonstrated by radial diffusion assay.

Patent No.: WO 036406
Commensal gram negative bacterium colonizing genitourinary and/or gastrointestinal mucosa for expressing antimicrobial proteins.
Applicant: Hamer DH (2006)
The present invention relates to a commensal bacterium which can colonize the genitourinary and/or gastrointestinal mucosa, and which, under suitable conditions, secretes a heterologous antimicrobial polypeptide fused with C-terminal secretion signal of hemolysin A. The secreted antimicrobial polypeptide is effective to inhibit infectivity by, or a pathogenic activity of, a pathogen. In a most preferred embodiment, the antimicrobial polypeptide inhibits HIV infection (e.g., fusion) and/or pathogens. The bacterium is a commensal strain of E. coli strain Nissle 1917, Pseudomonas aeruginosa, Veillonella parvula, fusobacterium, Bacillus, Lactococcus, Bifidobacterium, Bacteroides, or Neisseria.

Patent No.: WO 026237
Methods, systems and devices for noninvasive pulmonary delivery of lung surfactants.
Applicant: Niven R, Watanabe W, Thomas M, Brown D, Johnson M, Rairkar M (2006)
The invention is directed to methods, systems and devices for pulmonary delivery of aerosolized active agents in combination with pos. pressure ventilation therapy and methods of treating respiratory dysfunction. Thus, a lung surfactant compn. contg. a combination of DPPC, POPG, palmitic acid and a 21 mer peptide, sinapultide (KL4) consisting of lysine-leucine repeats, was prepd. Also, a study on healthy adult humans showed that the fraction of aerosolized KL4 deposited in the lungs was 16 to 25% of the aerosolized drug.

Patent No.: WO 008162
Alpha-defensins, particularly human neutrophil proteins (HNPs), as anthrax immunotherapeutics.
Applicant: Kum C, Kaufmann SHE, Gajendran N (2006)
The present invention relates to the use of an alpha-defensin in the manuf. of a medicament for the treatment, amelioration or prevention of a disease caused by Bacillus anthracis infection. In accordance with this invention, it was found that intoxication by Bacillus anthracis can be prevented by neutralization or inactivating toxin activity using defensins, in particular in conjunction with chemotherapy or a vaccine against B. anthracis. Thus, methods for the treatment of an B. anthracis infection as well as methods of protection against a B. anthracis infection, e.g. a vaccination are described. In a preferred embodiment, the alpha-defensin is one of the human neutrophil peptides (HNP1-4) naturally produced by granulocyte and lymphocyte. Provided are protein and cDNA sequences for HNP1-4, including for preproteins and mature peptides, as well as for mammalian homologs of human alpha-defensins.

Patent No.: WO 002520
The use of porcine beta-defensin-1 in vaccines for treating or preventing pertussis in vertebrates.
Applicant: Shokrollah E, Gerdts V, Babiuk L (2006)
Methods for the treatment and prevention of microbial infection, such as infections caused by bacteria, viruses, fungi and parasites are disclosed, as are adjuvants for use with vaccines against such microbes. The methods use porcine beta-defensins, such as porcine beta-defensin-1 and are particularly useful for treating or preventing infections caused by gram-neg. bacteria, such as pertussis.

Patent No.: US 7034007
Low-adenosine antisense oligonucleotides for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy and surfactant depletion.
Applicant: Nyce JW, Metzger WJ (2006)
An in vivo method of selectively delivering a nucleic acid to a target gene or mRNA, comprises the topical administration, e.g. to the respiratory system, of a subject of a therapeutic amt. of an oligonucleotide (oligo) that is antisense to a mRNA complementary to the gene in an amt. effective to reach the target polynucleotide and reducing or inhibiting expression. The compn. and formulations are used for prophylactic, preventive and therapeutic treatment of ailments assocd. with impaired respiration, lung allergy(ies) and/or inflammation and depletion lung surfactant or surfactant hypoprodn., such as pulmonary vasoconstriction, inflammation, allergies, allergic rhinitis, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction. The antisense oligos are designed to alleviate hyper-responsiveness to adenosine or increased levels of adenosine, wherein the antisense oligo is 7-60 nucleotides long and contains 15% adenosine. The treatment of this invention may be administered directly as an aerosol into the respiratory system of a subject so that the agent has direct access to the lungs, in an amt. effective to reduce or inhibit the symptoms of the ailment. Thus, the phosphorothioated oligo 5'-gatggaggggggcatggcggg-3' antisense to human adenosine A1 receptor mRNA, and related oligos specific for different regions of the A1 receptor mRNA for antisense to A2b and A3 receptors, are highly effective at countering or reducing effects mediated by the receptors they are targeted to. The activity of the antisense oligos is specific to the target and substitutively fails to inhibit another target, and results in extremely low or non-existent deleterious side effects or toxicity.

Patent No.: US 6984622
Use of lipopolysaccharides to manage corneal infections and wounds.
Applicant: Fleiszig SMJ, McNamara NA (2006)
The antibiotic polypeptide beta-defensin-2 (hBD-2) is expressed in the eye, and is useful for treating ocular wounds. hBD-2 is increased in the eye upon exposure to lipopolysaccharides (LPS). Administration of LPS to the eye thereby provides a useful method for increasing the amount of this antibiotic peptide in the eye.

Patent No.: US 281074
Affinity-based detection of biological targets using microarrays.
Applicant: Kulagina NV, Taitt CR, Anderson GP, Ligler FS (2006)
A method of biochem. identification by: providing a plurality of capture species bound to one or more substrates and suspected of having one or more biol. targets affinity bound to at least one capture species; detecting which capture species contain bound biol. targets to generate a binding pattern; and identifying the biol. target based on the binding pattern. The capture species are independently selected from the group consisting of antimicrobial peptides, cytotoxic peptides, antibiotics, and combinations thereof. A device having the capture species bound to the substrates. At least two of the capture species are capable of multi-specific binding to one or more biol. targets and may have overlapping but not identical affinity properties.